Related references
Note: Only part of the references are listed.Thymosin alpha(1)- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria
Ying Zhang et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with eAg-negative chronic hepatitis B
E. Loggi et al.
JOURNAL OF VIRAL HEPATITIS (2008)
Review of A Large Clinical Series: Association of Cumulative Fluid Balance on Outcome in Acute Lung Injury: A Retrospective Review of the ARDSnet Tidal Volume Study Cohort
Andrew L. Rosenberg et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2008)
Immunoregulation of thymosin alpha 1 treatment of cytomegalovirus infection accompanied with acute respiratory distress syndrome after renal transplantation
S. -M. Ji et al.
TRANSPLANTATION PROCEEDINGS (2007)
Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance
Luigina Romani et al.
BLOOD (2006)
Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients
JBAG Haanen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation
QQ Sun et al.
TRANSPLANT INTERNATIONAL (2006)
Activation of IKK by thymosin α1 requires the TRAF6 signalling pathway
P Zhang et al.
EMBO REPORTS (2005)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
YF Liaw et al.
LIVER INTERNATIONAL (2005)
Thymosin beta(4): actin-sequestering protein moonlights to repair injured tissues
AL Goldstein et al.
TRENDS IN MOLECULAR MEDICINE (2005)
Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling
L Romani et al.
BLOOD (2004)
Economic aspects of severe sepsis - A review of intensive care unit costs, cost of illness and cost effectiveness of therapy
H Burchardi et al.
PHARMACOECONOMICS (2004)
A pilot study of the safety and efficacy of thymosin α1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy
D Chadwick et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma
G Rasi et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer
E Garaci et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
The genome sequence of the SARS-associated coronavirus
MA Marra et al.
SCIENCE (2003)
The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis
HLY Chan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa
H Feltman et al.
MICROBIOLOGY-SGM (2001)
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application
E Garaci et al.
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY (2000)
Thymosinα1 is chemopreventive for lung adenoma formation in A/J mice
TW Moody et al.
CANCER LETTERS (2000)
Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma
G Rasi et al.
MELANOMA RESEARCH (2000)
Share Paper
